Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival. The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development. The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics. Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/29/13 | $35,000,000 | Series D |
Adage Capital Partners Advanced Technology Ventures Delphi Ventures Longwood Fund Morgenthaler | undisclosed |
